Spanish Health Ministry Awards Ion Beam the Proton Therapy Contract

The Ministry of Health has awarded the company Ion Beam Applications the contract for the implementation of ten proton therapy units in the National Health System (NHS), financed by the Amancio Ortega Gaona Foundation. In total, this proton radiotherapy equipment will be installed in seven autonomous communities, which will place Spain “at the forefront of this type of technology throughout Europe,” according to the Ministry of Health.

The Ministry of Health, in collaboration with the autonomous communities, has drawn up the specifications and put out to tender the equipment, which has been awarded in its entirety to the company Ion Beam Applications SA, for a total of €263.5 million.

On October 19th, 2021, an agreement was signed between, on the one hand, the Ministry of Health and the competent health departments of the autonomous communities of the Basque Country, Catalonia, Galicia, Andalusia, Valencia, the Canary Islands, and Madrid, and, on the other hand, the Amancio Ortega Gaona Foundation, for collaboration in the development of the plan drawn up by the Ministry of Health for the implementation of proton therapy in the National Health System.

Read more on the subject and find the most important business news of the day with our companion app Born2Invest.

The plan contemplates the installation of ten proton therapy equipment that will respond to the treatment needs of the entire SNS

The equipment will be distributed as follows: One unit in the Autonomous Community of the Basque Country, located in the Hospital Complex of Donostia, with a direct connection to the Onkologikoa facilities. Two teams in the Autonomous Community of Catalonia, located at the Parc Sanitari Pere Virgili in Barcelona.

One unit in the Autonomous Community of Galicia, located in the former Gil Casares Hospital next to the Hospital Clínico Universitario de Santiago de Compostela. Two units in the Autonomous Community of Andalusia, one located in the former Military Hospital of Seville and the other in the Maternal and Child Hospital of Malaga. One team in the Autonomous Community of Valencia, located at the Hospital Universitario de la Fe in Valencia. One unit in the Autonomous Community of the Canary Islands, located at the Hospital Universitario de Gran Canaria Dr. Negrín. Two teams in the Autonomous Community of Madrid, one located at the Hospital La Paz and the other at the Hospital de Fuenlabrada.

As stated in the agreement signed on October 19th, 2021, the funds required to finance the equipment will be provided by the Amancio Ortega Gaona Foundation

Once the contract with the company has been awarded and signed, the plan for the implementation and start-up of the equipment begins, which will be prepared and executed by each of the communities receiving the equipment.

This plan consists of four phases to be deployed in approximately 3-4 years: 1st Phase: Design and general arrangement of the implementation (concludes at the end of this year). Phase 2: Execution of projects and works (with an approximate duration of 18/24 months). 3rd Phase: Implementation of the equipment (lasting approximately 12 months). 4th Phase: Start-up and use of the equipment (training plan for professionals, authorization for the start-up of the equipment, and start of the treatments. With an approximate duration of 6 months).

__

(Featured image by ELG21 via Pixabay)

DISCLAIMER: This article was written by a third party contributor and does not reflect the opinion of Born2Invest, its management, staff or its associates. Please review our disclaimer for more information.

This article may include forward-looking statements. These forward-looking statements generally are identified by the words “believe,” “project,” “estimate,” “become,” “plan,” “will,” and similar expressions. These forward-looking statements involve known and unknown risks as well as uncertainties, including those discussed in the following cautionary statements and elsewhere in this article and on this site. Although the Company may believe that its expectations are based on reasonable assumptions, the actual results that the Company may achieve may differ materially from any forward-looking statements, which reflect the opinions of the management of the Company only as of the date hereof. Additionally, please make sure to read these important disclosures.

First published in diariofarma, a third-party contributor translated and adapted the article from the original. In case of discrepancy, the original will prevail.

Although we made reasonable efforts to provide accurate translations, some parts may be incorrect. Born2Invest assumes no responsibility for errors, omissions or ambiguities in the translations provided on this website. Any person or entity relying on translated content does so at their own risk. Born2Invest is not responsible for losses caused by such reliance on the accuracy or reliability of translated information. If you wish to report an error or inaccuracy in the translation, we encourage you to contact us.